AUTHORS
Jessica Marvel, MPH, Nicholas Kuypers, PhD2, Ver Bilano, MSc, PhD3, Samantha McStocker, BS4, Amanda Healey, MPH5, Connie Zhang, MPH6, Sarah Villard, PhD7, David Dingli, MD, PhD8
AFFILIATIONS
1 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
2 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
3 Novartis Pharmaceuticals Uk, London, United Kingdom
4 Folia Health, Boston, Massachusetts, United States
5 Folia Health, Boston, Massachusetts, United States
6 Folia Health, Boston, Massachusetts, United States
7 Folia Health, Boston, Massachusetts, United States
8 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement-mediated intravascular hemolysis. Fatigue is the most commonly reported symptom in PNH yet challenging to capture with clinical and laboratory assessments. Hematologic markers may normalize with treatment while fatigue persists, suggesting fatigue in PNH is driven by multiple factors.
Objective: The APPROACH study was designed to characterize the multidimensional burden of PNH, including fatigue, using longitudinal home-reported outcomes (HROs) collected alongside the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale, a validated patient-reported outcome (PRO) measure. Additionally, we explored differences across treatment groups.
Methods: In this ongoing, prospective, observational study (NCT06411626), designed in partnership with patients and clinicians, adults diagnosed with PNH used the Folia Health mobile health app to track symptoms, symptom severity, flares (defined as an exacerbation of a symptom), and FACIT-Fatigue scores for up to 12 months. Interim analyses included 115 participants enrolled between June 15, 2024, and May 1, 2026. Fatigue was assessed across symptom severity, FACIT-Fatigue scores, flare-associated symptom reporting, and monthly surveys capturing impacts on daily activities and work or school attendance. Participants included those receiving iptacopan (n=25), C5 inhibitors (C5is; n=29), no primary treatment (untreated; n=43), or other (n=18).
Results: At baseline, participants entered 61 unique symptoms and observations, with a mean (SD) of 11.2 (5.0) symptoms per participant (min = 0, max = 26). Fatigue was the most frequently selected symptom (96% of participants), with 2681 individual fatigue severity entries recorded during follow-up. Brain fog (84%), shortness of breath (80%), and dark urine (80%) were the next most frequently selected, underscoring substantial symptom burden. The most common flare-associated symptom was fatigue, occurring during 37% of flare days. Most participants (85%) reported fatigue affected daily life "some" or "a lot" at survey initiation and contributed to work/school absenteeism. Stress (17%) and changes in daily routine (12%) were the most frequently identified flare triggers, although 31% of participants could not identify a precipitating factor.
Across 8 commonly tracked symptoms (back pain, fatigue, brain fog, muscle spasms, muscle cramping, abdominal pain, shortness of breath, and bruising or discoloration) within the iptacopan, C5i, and untreated cohorts, participants receiving C5is reported the highest severity for 4 symptoms whereas those receiving iptacopan reported the lowest severity for 7 symptoms and had lower severity scores for all 8 symptoms compared to the untreated cohort. Difficulty sleeping was selected for tracking more often at baseline among untreated participants (61%) than those receiving iptacopan (20%) or C5is (38%). Mean (SD) baseline FACIT-Fatigue scores were higher (less fatigue) among participants receiving iptacopan (30.5 [15.2]) than those on C5is (25.1 [12.4]) or untreated (17.0 [11.3]); this difference persisted throughout follow-up. Untreated participants or those receiving C5is more frequently reported fatigue-related impacts on daily life and missed work or school days than those on iptacopan. A higher proportion of participants receiving eculizumab reported their treatment having greater impacts on daily life than ravulizumab or iptacopan. Fewer participants receiving iptacopan reported ≥1 flare than those on C5is (44% vs 62%).
Conclusions: Disease burden in PNH is multifactorial and shows substantial heterogeneity. The broad range of symptoms selected highlights aspects of the lived experience that may be overlooked in the clinical setting. Longitudinal HRO collection in APPROACH provides insights into disease, symptom, and treatment burden of PNH and their impacts on daily functioning and health-related quality of life. Observed differences in fatigue burden across treatment groups, including lower reported fatigue among participants receiving iptacopan, are descriptive and hypothesis generating and warrant further evaluation. The findings underscore the importance of continuous patient-centered data collection for advancing the understanding of PNH, while enabling patients to track symptoms and facilitate more informed discussions with their physicians to support disease management.
DISCLOSURES
David Dingli, MD, PhD: Sorrento - Honoraria; Regeneron - Honoraria; MSD - Honoraria; Alexion - Honoraria; Sanofi - Honoraria; Janssen - Honoraria; Bristol Myers Squibb - Honoraria; Novartis - Honoraria; Apellis - Honoraria; K36 Therapeutics - Research Funding; Novartis - Consultancy (Includes expert testimony); Sorrento - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Apellis - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)